Pharma BD Deal Intelligence

H. Lundbeck A/S / Alder BioPharmaceuticals, Inc.

2019 · Acquisition/Merger · $1.9B · Complete

Lundbeck's $1.95B bet on eptinezumab paid off: Vyepti hit DKK 2,909M in FY2024 (+72% CER) and led anti-CGRP growth in the U.S. at 11.2% share by September 2025—though its Phase 2/3 push into episodic cluster headache missed its primary endpoint outright.

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

Sep 16, 2019 BioPharma Dive Bullish

Piper Jaffray analyst Danielle Brill said 'we can't imagine any investor wanted to see Alder launch eptinezumab alone'—signaling relief that Lundbeck's…

Sep 17, 2019 FiercePharma Bullish

FiercePharma reported Alder had been seeking only an ex-US partner; Lundbeck escalated to a full buyout, suggesting strategic conviction in IV CGRP…

Feb 05, 2026 H. Lundbeck A/S (FY2024 results) Bullish

Vyepti (eptinezumab) revenue reached DKK 2,909 million in FY2024 following an increase of +72% at constant exchange rates; total group revenue a record DKK…

Source summaries from our enrichment pipeline; follow links for originals.

All 8 sources with sentiment breakdown →

Lundbeck agreed to acquire Alder BioPharmaceuticals for $18.00 per share upfront in cash plus a $2.00 per share CVR tied to FDA approval, totaling up to $1.95B. Lead asset eptinezumab (later approved as Vyepti) is the first IV-administered anti-CGRP monoclonal antibody for migraine prevention. Closed October 2019. Post-close, the thesis has been strongly validated commercially: Vyepti became one of Lundbeck's fastest-growing strategic brands, reaching DKK 2,909M in FY2024 (+72% CER) and DKK 3,254M in the first nine months of 2025 (+57% CER), and was the fastest-growing anti-CGRP in the U.S. at 11.2% market share by September 2025. A label-expansion attempt in episodic cluster headache failed, however: Lundbeck's Phase 2/3 trial (NCT04688775) missed its primary endpoint (-4.0 vs -4.6 weekly attacks for placebo, p=0.5048), so Vyepti remains a migraine-prevention-only asset.

Did it work? Outcome assessment

Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Eptinezumab (Vyepti) became a Lundbeck strategic growth brand: 2024 revenue reached DKK 2,909M (~$420M), up 72% CER, with momentum across all regions. A minor Vyepti obsolescence provision was noted in 2023 but did not impair the franchise, which continued strong double-digit growth.
Pipeline outcome
Assets Advanced
The lead asset eptinezumab won FDA approval in February 2020 (within months of deal close) and EU marketing authorization in 2021/2022, launching as Vyepti — the only IV anti-CGRP for migraine prevention — and scaling into a multi-hundred-million growth brand.

Key facts

Disease & market context

Migraine Prevention

$6.8B Global migraine drugs market 2024

Disease Overview

Migraine is a chronic neurologic disorder characterized by recurrent episodes of moderate-to-severe headache, often with photophobia, phonophobia, nausea, and aura. It affects roughly 40 million Americans (~12% prevalence), with 3-4 million suffering chronic migraine (≥15 headache days/month). It is a leading cause of disability among working-age adults and a major driver of healthcare utilization.

Competitive Landscape

At the September 2019 deal announcement, the CGRP migraine-prevention class was a year old and crowded. Three subcutaneous CGRP mAbs were already approved: Amgen/Novartis's Aimovig (erenumab, anti-CGRP receptor, May 2018), Teva's Ajovy (fremanezumab, Sept 2018), and Eli Lilly's Emgality (galcanezumab, Sept 2018). Eptinezumab was first-in-class as an IV-infused, quarterly anti-CGRP antibody, differentiating on rapid onset (efficacy within 24 hours) and adherence guaranteed by site-of-care administration—features that addressed compliance gaps in the SC mAb class. Older preventives included Allergan's Botox (onabotulinumtoxinA) for chronic migraine and oral generics (topiramate, propranolol, amitriptyline). The deal mattered because Lundbeck's neuroscience commercial infrastructure could compete in a crowded class where standalone Alder would have struggled. Piper Jaffray's Danielle Brill said 'we can't imagine any investor wanted to see Alder launch eptinezumab alone'. Vyepti was approved February 2020, has captured roughly 7% volume share by mid-2023, and reached DKK 2.9B in 2024 sales—evidence the deal-time strategic rationale played out, though the new gepant class (Nurtec ODT, Qulipta) and Lundbeck's own 2024 sales trajectory show the field continues to fragment.

Related deals — scored

DealYearValueOutcome
H. Lundbeck A/S / Alder BioPharmaceuticals, Inc. (this deal)2019$1.9B
H. Lundbeck A/S / Longboard Pharmaceuticals, Inc.2024$2.6B71
H. Lundbeck A/S / Prexton Therapeutics BV2018$1.1B14
Novartis AG / Advanced Accelerator Applications S.A.2017$3.9B98
Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program)2015$250M91
Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon)2000$450M89
Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals2015$3.5B86

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →